Skip to content

Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level

Impact of Echo-endoscopy Biopsy on the Circulating Tumor Cell Level in the Portal System in Pancreatic Adenocarcinoma Management Care

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04677244
Acronym
EUS-CTC
Enrollment
42
Registered
2020-12-21
Start date
2021-11-11
Completion date
2025-11-01
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Pancreas

Brief summary

The aim of this work is to evaluate the impact of endoscopic procedures on the circulating tumoral cells level in order to evaluate the potential effects of an endoscopic procedure in the management of pancreatic tumors.

Detailed description

The study will include 42 evaluable patients suspected of having pancreatic cancer and for whom an echo-endoscopic biopsy (EUS-FNA) and/or biliary drainage is planned. In these patients, a 6 ml blood sample will be taken from the portal vein before and after the echo-endoscopic biopsy of the pancreatic mass to determine: * the level of circulating tumor cells (CTC) per milliliter of blood, * cytological characteristics of CTCs (isolated, clustered, giant, and clustered including other cell types). A peripheral blood sample will also be taken to evaluate peripheral CTC levels and cytological characteristics before and after biopsy, as well as one month after biopsy. Patients will be evaluated every 6 months as part of their follow-up to assess the progression of their pathology and morbidity.

Interventions

PROCEDUREBlood sample in portal vein

A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.

Sponsors

Institut Paoli-Calmettes
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

prospective monocentric study

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Men and women aged 40-85 years old; * BMI\< 30 kg/m2; * Patients suspected of having pancreatic cancer for whom an ultrasound endoscopic biopsy and/or biliary drainage is planned; * Affiliation to, or beneficiary of, a social security scheme.

Exclusion criteria

* Woman who is pregnant or likely to become pregnant (without effective contraception) or breastfeeding ; * Person in an emergency situation, person of full age subject to a legal protection measure, or unable to express consent; * Biliary drainage or attempt at prior biliary drainage outside the center ; * Preliminary oncological treatment for pancreatic pathology covered by the study; * Clinical and/or image-visible (CT/MRI) carcinosis ; * Ascites visible on imaging (CT/MRI) ; * Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons; * Contraindications to an endoscopic procedure.

Design outcomes

Primary

MeasureTime frameDescription
Procedure impact5 minutes after procedureRate of patients with a CTC increase \> 4 cells/ml in the portal system after the endoscopic procedure

Countries

France

Contacts

Primary ContactDominique GENRE, MD
drci.up@ipc.unicancer.fr+33491223778

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026